Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 17;10(3):689.
doi: 10.3390/biomedicines10030689.

Definition of Castrate Resistant Prostate Cancer: New Insights

Juan Morote  1   2 , Adriana Aguilar  1 , Jacques Planas  1 , Enrique Trilla  1   2
Affiliations
Review

Definition of Castrate Resistant Prostate Cancer: New Insights

Juan Morote et al. Biomedicines. .

Abstract

The term castrate resistant prostate cancer (CRPC) was initially proposed by the Prostate Cancer Working Group 2 in 2008 to define the state of clinical and/or biochemical progression of prostate cancer (PCa) in an environment with very low serum testosterone concentration. Clinical progression is based on the radiological imaging proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) adapted to PCa. Biochemical progression is defined as an over 25% increase in serum prostate-specific antigen within two consecutive measurements separated by at least one week, and an absolute value above 2.0 ng/mL. Finally, the castrate environment is usually defined as a serum testosterone concentration maintained below 50 ng/dL or 1.7 nmol/dL. This definition does not incorporate the new and more accurate imaging modalities to assess clinical progression and the capability of the new biochemical measurements to assess the true castration environment. Ga-68-PSMA-11 PET CT/MRI and whole-body MRI are the new imaging modalities that should replace the classic thoracic CT scan, abdomino-pelvic CT scan, and technetium 99-m bone scintigraphy. In addition, Ga-68-PSMA-11 PET is the current basis for the new therapies targeting metastatic sites. Moreover, the current methods for measuring the very low serum testosterone concentrations in clinical laboratories are the widespread chemiluminescent assays, which are inappropriate, while LC-MSMS is the only method recommended to assess the castrate environment. In addition, recent research shows that serum luteinising hormone concentration associates better than serum testosterone with the castration environment, even when it is measured with LC-MSMS. In summary, the current definition of CRPC seems outdated. An extensive update to diagnose true CRPC is also needed to differentiate CRPC men with M0 (non-metastatic) from those with M1 (metastatic) CRPC. WC: 277.

Keywords: PSMA-PET; castration-resistance; free-testosterone; luteinising-hormone; prostate cancer; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Current definition of Castrate Resistant Prostate Cancer.
Figure 2
Figure 2
Proposed definition of Castrate Resistant Prostate Cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297. - PubMed
    1. Hansson N., Moll F., Schultheiss D., Krischel M. Remembering Charles B. Huggins’ Nobel Prize for Hormonal Treatment of Prostatic Cancer at its 50th Anniversary. Eur. Urol. 2016;69:971–972. doi: 10.1016/j.eururo.2016.01.030. - DOI - PubMed
    1. Byar D.P., Corle D.K. NCI Monographs. National Cancer Institute; Bethesda, MD, USA: 1988. Hormone Therapy for Prostate Cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies; pp. 165–170. - PubMed
    1. Schally A.V., Block N.L., Rick F.G. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate. 2017;77:1036–1054. doi: 10.1002/pros.23360. - DOI - PubMed
    1. Waxman J.H., Hendry W.F., Whitfield H.N., Oliver R.T. A long term follow-up of patients with advanced prostatic cancer treated with buserelin. Prog. Clin. Biol. Res. 1985;185A:271–277. - PubMed

LinkOut - more resources